专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09161930B2 Pharmaceutical composition for diabetic nephropathy and its preparation and application 有权
标题翻译：糖尿病肾病药物组合物及其制备及应用
公开(公告)号：US09161930B2
公开(公告)日：2015-10-20
申请号：US13287624
申请日：2011-11-02
申请人： Quan Zhu , Xinghua Shi , Dan Tang , Zhaoguang Zheng , Bao He , Tingting Duan , Fei Gu , Huiquan Cheng , Xiaoling Huang , Yanxia Huang , Rushang Wang
发明人： Quan Zhu , Xinghua Shi , Dan Tang , Zhaoguang Zheng , Bao He , Tingting Duan , Fei Gu , Huiquan Cheng , Xiaoling Huang , Yanxia Huang , Rushang Wang
IPC分类号： A61K31/27 , A61K9/00 , A61K9/20 , A61K9/48
CPC分类号： A61K31/27 , A61K9/0056 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2059 , A61K9/4875
摘要： The invention relates to application of 4,4′-diphenylmethane-bis(methyl) carbamates (DPMC) extracted and isolated from Cortex Mori and preparation of medicine for diabetic nephropathy. The pharmaceutical composition is made up of DPMC as active ingredient and the normal drug carriers, and the weight percentage of active ingredient is 0.1-99.5%. For the remarkable effect of prevention and cure for diabetic nephropathy and convenience for use, it will be a new facultative drug for patients.
摘要翻译：本发明涉及从Cortex Mori提取分离的4,4'-二苯基甲烷 - 双（甲基）氨基甲酸酯（DPMC）的应用和糖尿病性肾病药物的制备。药物组合物由作为活性成分的DPMC和正常药物载体组成，活性成分的重量百分比为0.1-99.5％。为了预防和治疗糖尿病肾病和使用便利性的显着效果，它将成为患者的新的兼性药物。

2. 发明授权

US08962806B2 Humanized monoclonal antibodies and methods of use 有权
标题翻译：人源化单克隆抗体及其使用方法
公开(公告)号：US08962806B2
公开(公告)日：2015-02-24
申请号：US12810888
申请日：2008-12-29
申请人： Wayne Marasco , Jianhua Sui , Quan Zhu , Thomas Kupper
发明人： Wayne Marasco , Jianhua Sui , Quan Zhu , Thomas Kupper
IPC分类号： C07K16/30 , C07K16/28 , C12P21/08 , A61K39/395 , C07K14/715
CPC分类号： C07K16/2866 , C07K14/7158 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
摘要翻译：本发明包含与趋化因子受体CCR4结合的人源化单克隆抗体。该抗体衍生自Mab 1567并识别相同的表位。本发明抗体与CCR4的结合抑制配体介导的活性，并用于治疗癌症。此外，抗体与疫苗组合使用以抑制调节性T细胞的活性。

3. 发明申请

US20120079113A1 Method, Apparatus, and System for Mobile Virtual Private Network Communication 有权
标题翻译：移动虚拟专用网络通信的方法，装置和系统
公开(公告)号：US20120079113A1
公开(公告)日：2012-03-29
申请号：US13302860
申请日：2011-11-22
申请人： Quan Zhu , Dong Guo
发明人： Quan Zhu , Dong Guo
IPC分类号： G06F11/00 , G06F15/16
CPC分类号： H04W8/26 , H04L29/12226 , H04L61/2015 , H04L63/0272 , H04W40/24 , H04W76/10 , H04W84/16 , H04W88/16
摘要： A mobile packet gateway obtains a network address of the terminal and a network address of a gateway virtual interface. The network address of the gateway virtual interface and the network address of the terminal belong to a same network segment. A virtual interface is created for a Packet Data Protocol Context (PDP context) of the MS according to the network address of the gateway virtual interface. A network segment address of a branch network served by the MS is obtained from the MS through the virtual interface according to a dynamic routing protocol.
摘要翻译：移动分组网关获取终端的网络地址和网关虚拟接口的网络地址。网关虚拟接口的网络地址和终端的网络地址属于同一个网段。根据网关虚拟接口的网络地址为MS的分组数据协议上下文（PDP上下文）创建虚拟接口。根据动态路由协议，通过虚拟接口从MS获取由MS服务的分支网络的网段地址。

4. 发明授权

US09084108B2 Method, apparatus, and system for mobile virtual private network communication 有权
标题翻译：用于移动虚拟专用网络通信的方法，装置和系统
公开(公告)号：US09084108B2
公开(公告)日：2015-07-14
申请号：US13302860
申请日：2011-11-22
申请人： Quan Zhu , Dong Guo
发明人： Quan Zhu , Dong Guo
IPC分类号： G06F15/173 , H04W8/26 , H04L29/06 , H04L29/12 , H04W40/24 , H04W76/02 , H04W84/16 , H04W88/16
CPC分类号： H04W8/26 , H04L29/12226 , H04L61/2015 , H04L63/0272 , H04W40/24 , H04W76/10 , H04W84/16 , H04W88/16
摘要： A mobile packet gateway obtains a network address of the terminal and a network address of a gateway virtual interface. The network address of the gateway virtual interface and the network address of the terminal belong to a same network segment. A virtual interface is created for a Packet Data Protocol Context (PDP context) of the MS according to the network address of the gateway virtual interface. A network segment address of a branch network served by the MS is obtained from the MS through the virtual interface according to a dynamic routing protocol.
摘要翻译：移动分组网关获取终端的网络地址和网关虚拟接口的网络地址。网关虚拟接口的网络地址和终端的网络地址属于同一个网段。根据网关虚拟接口的网络地址为MS的分组数据协议上下文（PDP上下文）创建虚拟接口。根据动态路由协议，通过虚拟接口从MS获取由MS服务的分支网络的网段地址。

5. 发明申请

US20120053236A1 PHARMACEUTICAL COMPOSITION FOR DIABETIC NEPHROPATHY AND ITS PREPARATION AND APPLICATION 有权
标题翻译：用于糖尿病患者的药物组合物及其制备和应用
公开(公告)号：US20120053236A1
公开(公告)日：2012-03-01
申请号：US13287624
申请日：2011-11-02
申请人： Quan Zhu , Xinghua Shi , Dan Tang , Zhaoguang Zheng , Bao He , Tingting Duan , Fei Gu , Huiquan Cheng , Xiaoling Huang , Yanxia Huang , Rushang Wang
发明人： Quan Zhu , Xinghua Shi , Dan Tang , Zhaoguang Zheng , Bao He , Tingting Duan , Fei Gu , Huiquan Cheng , Xiaoling Huang , Yanxia Huang , Rushang Wang
IPC分类号： A61K31/27 , A61P13/12
CPC分类号： A61K31/27 , A61K9/0056 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2059 , A61K9/4875
摘要： The invention relates to application of 4,4′-diphenylmethane-bis(methyl) carbamates (DPMC) extracted and isolated from Cortex Mori and preparation of medicine for diabetic nephropathy. The pharmaceutical composition is made up of DPMC as active ingredient and the normal drug carriers, and the weight percentage of active ingredient is 0.1-99.5%. For the remarkable effect of prevention and cure for diabetic nephropathy and convenience for use, it will be a new facultative drug for patients.
摘要翻译：本发明涉及从Cortex Mori提取分离的4,4'-二苯基甲烷 - 双（甲基）氨基甲酸酯（DPMC）的应用和糖尿病性肾病药物的制备。药物组合物由作为活性成分的DPMC和正常药物载体组成，活性成分的重量百分比为0.1-99.5％。为了预防和治疗糖尿病肾病和使用便利性的显着效果，它将成为患者的新的兼性药物。

6. 发明申请

US20070255041A1 Bioengineered Vehicles for Targeted Nucleic Acid Delivery 审中-公开
标题翻译：用于靶向核酸递送的生物工程车辆
公开(公告)号：US20070255041A1
公开(公告)日：2007-11-01
申请号：US11620467
申请日：2007-01-05
申请人： James Huston , Pierre Wils , Quan Zhu , Oliver Laurent , Wayne Marasco , Daniel Scherman
发明人： James Huston , Pierre Wils , Quan Zhu , Oliver Laurent , Wayne Marasco , Daniel Scherman
IPC分类号： C07K14/00
CPC分类号： A61K48/00 , A61K2039/505 , C07K16/32 , C07K2317/622 , C07K2319/00 , C12N15/87
摘要： There is disclosed a gene-delivery compound comprising: (A) a single-chain binding polypeptide having at least one effector segment which includes at least one cysteinyl residue; and (B) a nucleic acid-binding moiety which is coupled to the polypeptide via the cysteinyl residue. There is disclosed also a gene-delivery compound comprising: (A) a single-chain, binding polypeptide having at least one effector segment which includes at least one cysteinyl residue; (B) a lipid-associating moiety which is coupled to the polypeptide via the cysteinyl residue. Additionally disclosed are compositions comprising the above-mentioned compounds and a nucleic acid.
摘要翻译：公开了一种基因递送化合物，其包含：（A）具有至少一个效应子段的单链结合多肽，其包含至少一个半胱氨酰残基; 和（B）通过半胱氨酰残基与多肽偶联的核酸结合部分。还公开了一种基因递送化合物，其包含：（A）具有至少一个效应子段的单链结合多肽，其包含至少一个半胱氨酰残基; （B）通过半胱氨酰残基与多肽偶联的脂质缔合部分。另外公开的是包含上述化合物和核酸的组合物。

7. 发明申请

US20120054460A1 METHOD AND SYSTEM FOR STORAGE SYSTEM MIGRATION 审中-公开
标题翻译：存储系统移植的方法和系统
公开(公告)号：US20120054460A1
公开(公告)日：2012-03-01
申请号：US13217739
申请日：2011-08-25
申请人： Qiao Qing Dai , Min Fang , Hui Xiang Gu , Zhen Quan Zhu
发明人： Qiao Qing Dai , Min Fang , Hui Xiang Gu , Zhen Quan Zhu
IPC分类号： G06F12/02
CPC分类号： H04L67/1097 , G06F3/0611 , G06F3/0647 , G06F3/067
摘要： A method, migration manager, and system of storage system migration. The method includes creating a first zone including a host system in a first SAN-based storage system and an in-band SAN virtualization storage node. The method creates a second zone including a backend storage system in the first SAN-based storage system and the in-band SAN virtualization storage node. A storage unit exported by the backend storage system is mapped to a virtual storage unit created on the in-band SAN virtualization storage node, and a third zone including the host system and backend storage system in the first SAN-based storage system is canceled. The method is performed without disrupting an existing connection path between the host system and the backend storage system in the first SAN-based storage system. A migration manager of a migration system migrates a first SAN-based storage system into an in-band SAN virtualization storage system.
摘要翻译：一种方法，迁移管理器和存储系统迁移系统。该方法包括在第一基于SAN的存储系统和带内SAN虚拟化存储节点中创建包括主机系统的第一区域。该方法在第一个基于SAN的存储系统和带内SAN虚拟化存储节点中创建一个包括后端存储系统的第二个区域。由后端存储系统导出的存储单元被映射到在带内SAN虚拟化存储节点上创建的虚拟存储单元，并且在第一基于SAN的存储系统中包括主机系统和后端存储系统的第三区域被取消。执行该方法而不中断在第一基于SAN的存储系统中的主机系统与后端存储系统之间的现有连接路径。迁移系统的迁移管理器将第一个基于SAN的存储系统迁移到带内SAN虚拟化存储系统。

8. 发明申请

US20110171210A1 HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE 有权
标题翻译：人类单克隆抗体及其使用方法
公开(公告)号：US20110171210A1
公开(公告)日：2011-07-14
申请号：US12810888
申请日：2008-12-29
申请人： Wayne Marasco , Jianhua Sui , Quan Zhu , Thomas Kupper
发明人： Wayne Marasco , Jianhua Sui , Quan Zhu , Thomas Kupper
IPC分类号： A61K39/395 , C07K16/28 , C12N5/07 , C12N5/0783 , C07H21/00 , C12N15/63 , C12N5/09 , C12N5/10 , A61P35/00 , A61P37/04 , A61P31/18 , A61P31/12 , A61P31/04 , A61P35/02
CPC分类号： C07K16/2866 , C07K14/7158 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
摘要翻译：本发明包含与趋化因子受体CCR4结合的人源化单克隆抗体。该抗体衍生自Mab 1567并识别相同的表位。本发明抗体与CCR4的结合抑制配体介导的活性，并用于治疗癌症。此外，抗体与疫苗组合使用以抑制调节性T细胞的活性。

9. 发明申请

US20110053872A1 Pharmaceutical Composition For Preventing And Treating Diabetic Nephropathy And The Preparation Method Thereof 审中-公开
标题翻译：用于预防和治疗糖尿病肾病的药物组合物及其制备方法
公开(公告)号：US20110053872A1
公开(公告)日：2011-03-03
申请号：US12810571
申请日：2009-04-01
申请人： Quan Zhu , Xinghua Shi , Dan Tang , Zhaoguang Zheng , Bao He , Tingting Duan , Fei Gu , Huiquan Cheng , Xiaoling Huang , Yanxia Huang , Rushang Wang
发明人： Quan Zhu , Xinghua Shi , Dan Tang , Zhaoguang Zheng , Bao He , Tingting Duan , Fei Gu , Huiquan Cheng , Xiaoling Huang , Yanxia Huang , Rushang Wang
IPC分类号： A61K31/7048 , A61K31/353 , A61P3/10
CPC分类号： A61K31/7048 , A61K31/352
摘要： The present invention relates to a pharmaceutical composition for preventing and treating diabetic complications, mainly referring to diabetic nephropathy, and the pharmaceutical composition comprises one or both of calycosin and calycosin-7-O-β-D-glucoside as 0.1˜99.5% by weight based on the total weight of the composition, and the conventional drug carrier. The pharmaceutical composition could significantly prevent and treat diabetic nephropathy, with the convenience of quality control and administration, which provides a new drug candidate for patients with diabetic nephropathy.
摘要翻译：本发明涉及一种预防和治疗糖尿病并发症的药物组合物，主要涉及糖尿病性肾病，并且该药物组合物包含赤藓糖苷和胡萝卜素-7-O-＆bgr-D-葡萄糖苷之一或两者为0.1〜99.5％基于组合物的总重量和常规药物载体的重量。药物组合物可以显着预防和治疗糖尿病肾病，方便质量控制和给药，为糖尿病肾病患者提供新的候选药物。

10. 发明申请

US20100267819A1 PHARMACEUTICAL COMPOSITION FOR DIABETIC NEPHROPATHY AND ITS PREPARATION AND APPLICATION 审中-公开
标题翻译：用于糖尿病患者的药物组合物及其制备和应用
公开(公告)号：US20100267819A1
公开(公告)日：2010-10-21
申请号：US12823305
申请日：2010-06-25
申请人： QUAN ZHU , Xinghua Shi , Dan Tang , Zhaoguang Zheng , Bao He , Tingting Duan , Fei Gu , Huiquan Cheng , Xiaoling Huang , Yanxia Huang , Rushang Wang
发明人： QUAN ZHU , Xinghua Shi , Dan Tang , Zhaoguang Zheng , Bao He , Tingting Duan , Fei Gu , Huiquan Cheng , Xiaoling Huang , Yanxia Huang , Rushang Wang
IPC分类号： A61K31/352 , C07D311/06 , A61P3/10
CPC分类号： A61K31/353 , A61K9/0056 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2059 , A61K9/4875 , A61K31/37
摘要： The invention relates to a pharmaceutical composition for diabetic nephropathy and its preparation, and the application in preparing of medicine for diabetic nephropathy. The pharmaceutical composition is made up of at least one of 7-hydroxycoumarin and 7-hydroxy-6-methoxycoumarin as active ingredient, and the weight percentage of active ingredient is 0.1-99.5%. Moreover, the pharmaceutical composition is mainly used for the prevention and cure of diabetic nephropathy. For the abundant material, remarkable effect on prevention and cure for diabetic nephropathy and convenience for use, it will be a new facultative drug for patients.
摘要翻译：本发明涉及一种糖尿病肾病药物组合物及其制备方法及其在制备糖尿病肾病药物中的应用。药物组合物由7-羟基香豆素和7-羟基-6-甲氧基香豆素中的至少一种作为活性成分组成，活性成分的重量百分比为0.1-99.5％。此外，该药物组合物主要用于预防和治疗糖尿病肾病。对于丰富的材料，对糖尿病肾病的预防和治疗效果显着，使用方便，将成为患者新的兼性药物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式